These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7215069)

  • 21. Vasopressin and hypertension in man.
    Morton JJ; Padfield PL
    J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S101-6. PubMed ID: 2434762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of vasopressin to the maintenance of blood pressure in deoxycorticosterone-salt induced malignant hypertension in spontaneously hypertensive rats.
    Hiwatari M; Abrahams JM; Saito T; Johnston CI
    Clin Sci (Lond); 1986 Feb; 70(2):191-8. PubMed ID: 3956109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence against a pressor role for vasopressin in spontaneous hypertension.
    Sladek CD; Blair ML; Mangiapane M
    Hypertension; 1987 Apr; 9(4):332-8. PubMed ID: 2951326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Vasopressin in Rat Models of Salt-Dependent Hypertension.
    Prager-Khoutorsky M; Choe KY; Levi DI; Bourque CW
    Curr Hypertens Rep; 2017 May; 19(5):42. PubMed ID: 28451854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats.
    Maeda C; Schaan B; Oliveira E; Oliveira V; De Angelis K; Irigoyen M
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):574-80. PubMed ID: 17581211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Central vasopressin is required for the complete development of deoxycorticosterone-salt hypertension in rats with hereditary diabetes insipidus.
    Liang J; Toba K; Ouchi Y; Nagano K; Akishita M; Kozaki K; Ishikawa M; Eto M; Orimo H
    J Auton Nerv Syst; 1997 Jan; 62(1-2):33-9. PubMed ID: 9021647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI
    Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate salt hypertensive rats.
    Intengan HD; He G; Schiffrin EL
    Hypertension; 1998 Oct; 32(4):770-7. PubMed ID: 9774378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine control of salt and water excretion: the role of vasopressin in DOCA-salt hypertension.
    Hofbauer KG; Mah SC; Baum HP; Hänni H; Wood JM; Kraetz J
    J Cardiovasc Pharmacol; 1984; 6 Suppl 1():S184-91. PubMed ID: 6204139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma vasopressin concentrations and effects of vasopressin antiserum on blood pressure in rats with malignant two-kidney Goldblatt hypertension.
    Möhring J; Möhring B; Petri M; Haack D
    Circ Res; 1978 Jan; 42(1):17-22. PubMed ID: 618598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methionine-enkephalin and vasopressin in SHR: effects of dehydration.
    Ota K; Share L; Crofton JT; Brooks DP
    Am J Physiol; 1986 Jun; 250(6 Pt 2):R1007-13. PubMed ID: 3717373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of vasopressin and the sympathetic nervous system in the early phase of high sodium one-kidney renal hypertension.
    Hinojosa C; Haywood JR
    Hypertension; 1984; 6(6 Pt 1):848-54. PubMed ID: 6240442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylprednisolone-induced hypertension in the rat: evidence against the role of plasma volume changes, vasopressin and renal prostaglandin E2.
    Ramos-Frendo B; Eloy L; Grünfeld JP
    J Hypertens; 1985 Oct; 3(5):461-7. PubMed ID: 3864857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of brain histamine synthesis increases food intake and attenuates vasopressin response to salt loading in rats.
    Tuomisto L; Yamatodani A; Jolkkonen J; Sainio EL; Airaksinen MM
    Methods Find Exp Clin Pharmacol; 1994 Jun; 16(5):355-9. PubMed ID: 7934314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative contribution of vasopressin and angiotensin II to the altered renal microcirculatory dynamics in two-kidney Goldblatt hypertension.
    Ichikawa I; Ferrone RA; Duchin KL; Manning M; Dzau VJ; Brenner BM
    Circ Res; 1983 Nov; 53(5):592-602. PubMed ID: 6194914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute interaction of vasopressin and neurogenic mechanisms in DOC-salt hypertension.
    Matsuguchi H; Schmid PG
    Am J Physiol; 1982 Jan; 242(1):H37-43. PubMed ID: 7058911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of acute vasopressin infusion on blood pressure and plasma angiotensin II in normotensive and DOCA-salt hypertensive rats.
    Morton JJ; Garcia del Rio C; Hughes MJ
    Clin Sci (Lond); 1982 Feb; 62(2):143-9. PubMed ID: 7053914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of vasopressin in the control of arterial pressure.
    McNeill JR
    Can J Physiol Pharmacol; 1983 Nov; 61(11):1226-35. PubMed ID: 6362804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of the sympathetic nerve in the pathogenesis of hypertension by partial nephrectomy and salt loading in rat].
    Shima H; Nishio I; Tsuda K; Hano T; Kuchii M; Masuyama Y
    Nihon Jinzo Gakkai Shi; 1987 Jan; 29(1):73-9. PubMed ID: 3586399
    [No Abstract]   [Full Text] [Related]  

  • 40. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats.
    Bouby N; Hassler C; Bankir L
    Life Sci; 1999; 65(10):991-1004. PubMed ID: 10499867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.